期刊
CLINICAL INFECTIOUS DISEASES
卷 63, 期 -, 页码 S12-S23出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciw220
关键词
hepatitis C virus; human immunodeficiency virus; coinfection; drug interactions; direct-acting antivirals
资金
- Merck Co.
- National Institutes of Health [R01 DA040499]
Roughly one-third of individuals living with the human immunodeficiency virus (HIV) are coinfected with the hepatitis C virus (HCV) due to shared routes of transmission. HIV accelerates the progression of HCV disease; thus, coinfected individuals are at high priority for HCV treatment. Several new HCV therapies, called direct-acting antiviral agents (DAAs), are available that achieve cure rates of > 90% in many patient populations including individuals with HIV. The primary consideration in treating HCV in HIV-infected persons is the potential for drug interactions. We describe the clinical pharmacology and drug interaction potential of the DAAs, review the interaction data with DAAs and antiretroviral agents, and identify the knowledge gaps in the pharmacologic aspects of treating HCV in individuals with HIV coinfection. This review will focus on DAAs that have received regulatory approval in the United States and Europe and agents in late stages of clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据